The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups
Open accessAbstract
Schizophrenia is characterized by physical (mainly metabolic and cardiovascular) comorbidity and shortened lifespan. High sensitivity C-reactive protein (hs-CRP), an inflammatory marker of hepatic origin linked to metabolic and cardiovascular diseases and mortality in the general population, has been reported to be elevated in people with schizophrenia. However, the relationship of hs-CRP to psychiatric and medical risk factors, after controlling for potentially confounding variables such as smoking, is not well established in schizophrenia. We assessed hs-CRP levels along with various demographic, psychiatric, and metabolic measures in 88 clinically stable outpatients with schizophrenia or schizoaffective disorder and 71 age epoch-matched comparison subjects with no history of a major psychiatric illness. hs-CRP levels were significantly higher in individuals with schizophrenia than in comparison subjects. Higher hs-CRP levels in the schizophrenia group were associated with female gender, more severe negative symptoms, greater medical comorbidity, and worse metabolic risk factors including BMI, fasting glucose, and hemoglobin A1c levels. hs-CRP was not related to age, race, education, smoking status, antipsychotic dosage, or cognitive impairment. Longitudinal studies are needed to investigate the relationship between hs-CRP and long-term health outcomes including metabolic syndrome, cardiovascular disease, and mortality in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and used in clinical practice mainly as a biomarker of infection, chronic disease state, and chronic low-grade inflammation [30,32].”
From C-Reactive protein as a biomarker for major depressive disorder? (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,710
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
Scale for the Assessment of Negative Symptoms
Andreasen, N. C. (1982) · PsycTESTS Dataset · doi:10.1037/t12696-000 · Cited by 1,888
Black, S., Kushner, I., & Samols, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400025200 · Cited by 1,844
Shunk, A. W., Davis, A. S., & Dean, R. S. (2006) · Applied Neuropsychology · doi:10.1207/s15324826an1304_9 · Cited by 1,540
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488
Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D. D., & Ho, B. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.040 · Cited by 956
Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population
Parmelee, P. A., THURAS, P. D., Katz, I. R., & Lawton, M. P. (1995) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1995.tb06377.x · Cited by 952
Socioeconomic status and health: the role of subjective social status
Demakakos, P., Nazroo, J., Breeze, E., & Marmot, M. (2008) · Social Science & Medicine · doi:10.1016/j.socscimed.2008.03.038 · Cited by 719
Socioeconomic Status And Health
(2002) · Health Affairs · doi:10.1377/hlthaff.21.2.47 · Cited by 667
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
Ridker, P. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.052 · Cited by 635
Zeyda, M., Farmer, D., Todoric, J., Aszmann, O. C., Speiser, M., Györi, G., Zlabinger, G. J., & Stulnig, T. M. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803632 · Cited by 575
Tracy, R. P., Psaty, B. M., Macy, E., Bovill, E. G., Cushman, M., Cornell, E. S., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.10.2167 · Cited by 539
Is schizophrenia a syndrome of accelerated aging?
Kirkpatrick, B., Messias, E., Harvey, P. D., Fernandez-Egea, E., & Bowie, C. R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm140 · Cited by 335
Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.066 · Cited by 332
Ruiz‐Canela, M., Zazpe, I., Shivappa, N., Hébert, J. R., Sánchez‐Tainta, A., Corella, D., Salas‐Salvadó, J., Fitó, M., Lamuela-Raventós, R. M., Rekondo, J., et al. (2015) · British Journal Of Nutrition · doi:10.1017/s0007114514004401 · Cited by 285
C-Reactive Protein Levels in Schizophrenia
Miller, B. J., Culpepper, N. H., & Rapaport, M. H. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.micu.020813 · Cited by 263
Lopresti, A. L., & Drummond, P. D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.005 · Cited by 231
Dickerson, F., Stallings, C. R., Origoni, A. E., Boronow, J. J., & Yolken, R. H. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.022 · Cited by 205
Osborn, D. P. J., Hardoon, S., Omar, R. Z., Holt, R. I. G., King, M., Larsen, J., Marston, L., Morris, R. W., Nazareth, I., Walters, K., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2133 · Cited by 200
Fucetola, R. P., Seidman, L. J., Kremen, W. S., Faraone, S. V., Goldstein, J. M., & Tsuang, M. T. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00240-7 · Cited by 165
Jones, A. L., Mowry, B. J., Pender, M. P., & Greer, J. M. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01305.x · Cited by 155
Cognition in schizophrenia : impairments, importance, and treatment strategies
Sharma, T., & Harvey, P. D. (2000) · Oxford University Press eBooks · Cited by 146
Toomey, R., Kremen, W. S., Simpson, J. C., SAMSON, J. A., Seidman, L. J., Lyons, M. J., Faraone, S. V., & Tsuang, M. T. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.3.371 · Cited by 135
Inflammation and schizophrenia
Fan, X., GOFF, D. C., & Henderson, D. C. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.789 · Cited by 121
Hinze‐Selch, D., Däubener, W., Eggert, L., Erdag, S., Stoltenberg, R. L., & Wilms, S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm010 · Cited by 117
Wellness within illness: Happiness in schizophrenia
Palmer, B. W., Martin, A. S., Depp, C. A., Glorioso, D. K., & Jeste, D. V. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.07.027 · Cited by 113
Self-citationCognitive impairment of executive function as a core symptom of schizophrenia
Wobrock, T., Ecker, U. K. H., Scherk, H., Schneider-Axmann, T., Falkai, P., & Gruber, O. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701849986 · Cited by 102
García‐Rizo, C., Fernández-Egea, E., Oliveira, C., Justicia, A., Bernardo, M., & Kirkpatrick, B. W. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.08.014 · Cited by 89
C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia
Fawzi, M. H., Fawzi, M. M., Fawzi, M. M., & Said, N. S. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.05.010 · Cited by 89
Hefner, G., Shams, M. E. E., Unterecker, S., Falter, T., & Hiemke, C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3976-0 · Cited by 83
Almeida, O. P., Hankey, G. J., Yeap, B. B., Golledge, J., Norman, P. E., & Flicker, L. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111882 · Cited by 82
Dickerson, F., Stallings, C. R., Origoni, A. E., Vaughan, C., Khushalani, S., & Yolken, R. H. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.10.003 · Cited by 81
Akanji, A. O., OHAERI, J. U., Al-Shammri, S., & Fatania, H. R. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.010 · Cited by 68
Jin, H., Folsom, D. P., Sasaki, A., Mudaliar, S. R. D., Henry, R. R., Torres, M., Golshan, S., Glorioso, D., & Jeste, D. V. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.029 · Cited by 55
Self-citationMortality in schizophrenia: clinical and serological predictors
Dickerson, F., Stallings, C., Origoni, A., Schroeder, J., Khushalani, S., & Yolken, R. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt113 · Cited by 50
Body Mass Index Identified as an Independent Predictor of Psychiatric Readmission
Manu, P., Khan, S., Radhakrishnan, R., Russ, M. J., Kane, J. M., & Correll, C. U. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08795 · Cited by 45
Executive dysfunction in schizophrenia
Leicester, S. (2002) · Research Online (University of Wollongong) · Cited by 44
Executive Dysfunction in Schizophrenia
Palmer, B. W., & Heaton, R. K. (2000) · doi:10.1093/oso/9780192629937.003.0003 · Cited by 39
Self-citationDietrich, T., García, R. I., de Pablo, P., Schulze, P. C., & Hoffmann, K. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328270b913 · Cited by 36
Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia
Tay, Y. H., Nurjono, M., & Lee, J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.03.023 · Cited by 35
Sicras‐Mainar, A., Rejas, J., Navarro‐Artieda, R., & Blanca-Tamayo, M. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.07.003 · Cited by 35
Rossi, I. A., Bochud, M., Bovet, P., Paccaud, F. M., Waeber, G., Vollenweider, P., & Taffé, P. (2012) · European Journal of Epidemiology · doi:10.1007/s10654-012-9671-0 · Cited by 34
Miller, B. J., Kandhal, P. K., Rapaport, M. H., Mellor, A. L., & Buckley, P. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.12.005 · Cited by 31
Fawzi, M. H., Fawzi, M. M., Said, N. S., Fawzi, M. M., Fouad, A. A., & Abdel-Moety, H. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.057 · Cited by 25
Protopopová, D., Masopust, J., Malý, R., Vališ, M., & Bažant, J. (2012) · PubMed · Cited by 23
Rogowski, O., Shapira, I., Toker, S., Melamed, S., Shirom, A., Berliner, S. A., & Zeltser, D. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802939 · Cited by 22
Onat, A., Can, G., Hergenç, G., Uğur, M., & Yüksel, H. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.10.010 · Cited by 17
Foley, D. L., Mackinnon, A. J., Morgan, V. A., Watts, G. F., Shaw, J. E., Magliano, D. J., Castle, D. J., McGrath, J. J., Waterreus, A. J., & Galletly, C. A. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414565476 · Cited by 12
Saatçioğlu, Ö., Kalkan, M., Fıstikçı, N., Erek, Ş., & Kılıc, K. C. (2015) · Psychiatric Quarterly · doi:10.1007/s11126-015-9384-0 · Cited by 10
Konishi, S., Parajuli, R. P., Takane, E., Maharjan, M., Tachibana, K., Jiang, H., Pahari, K., Inoue, Y., Umezaki, M., & Watanabe, C. (2014) · American Journal of Physical Anthropology · doi:10.1002/ajpa.22470 · Cited by 9
Cited by
Sorted by citations
Lee, E. E., Depp, C., Palmer, B. W., Glorioso, D., Daly, R., Liu, J., Tu, X. M., Kim, H.-C., Tarr, P., Yamada, Y., et al. (2019) · International Psychogeriatrics · doi:10.1017/s1041610218002120 · Cited by 286
Self-citationSocioeconomic status and inflammation: a meta-analysis
Muscatell, K. A., Brosso, S. N., & Humphreys, K. L. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0259-2 · Cited by 294
Nguyen, T. T., Kosciolek, T., Maldonado, Y., Daly, R. E., Martin, A. S., McDonald, D., Knight, R., & Jeste, D. V. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.014 · Cited by 260
Self-citationMisiak, B., Stańczykiewicz, B., Kotowicz, K., RYBAKOWSKI, J. K., Samochowiec, J., & Frydecka, D. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.015 · Cited by 209
C-Reactive protein as a biomarker for major depressive disorder?
Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., & Volpe, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031616 · Cited by 171
Metadata
- Authors
- Joseph, J., Depp, C., Martin, A. S., Daly, R. E., Glorioso, D. K., Palmer, B. W., & Jeste, D. V.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Jeste, Dilip V.
- ORCID
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 168
- Issue
- 1-2
- Pages
- 456-460
- ISSN
- 0920-9964 (ISSN-L)
- PMC
- PMC4591213
- OpenAlex
- W2142231500
- Cited by
- 109
- References
- 55
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 9 · 2022: 14 · 2021: 8 · 2020: 8 · 2019: 11 · 2018: 15 · 2017: 15 · 2016: 13
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Mental Health (MH019934, R01MH094151, T32MH019934)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- high-sensitivity C-reactive protein, schizophrenia
- MeSH terms
- Adult, Aged, C-Reactive Protein, Female, Humans, Longitudinal Studies, Male, Metabolic Diseases, Middle Aged, Outpatients, Psychotic Disorders, Risk Factors, Schizophrenia, Sex Characteristics, Biomarkers, Comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
